UK Markets closed

Inventiva S.A. (0RNK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.92+0.21 (+3.68%)
At close: 11:42AM GMT
Full screen
Previous close5.71
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume204,711
Avg. volumeN/A
Market cap112.547M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-0.99
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), Long Island City (New York, United States), January 30, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Keple

  • Globe Newswire

    Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023

    Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ General Meeting. The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oc

  • Globe Newswire

    Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

    Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population to patients with NASH and compensated cirrhosis Confirmatory trial of lanifibranor clinical benefits, which was initially planned to be evaluated in Part 2 of NATiV3 trial in patients with NASH and F2/F3 fibrosis, is now planned t